Peripheral Neurotrophin Trajectories, Coping and Depressive Symptoms During Primary Treatment in Ovarian and Endometrial Cancer: A Prospective Longitudinal Study

Background: Changes in peripheral neurotrophin concentrations during cancer treatment may reflect tumour biology, haematological alterations or systemic inflammation, and neurotrophins have been linked to depression. We examined neurotrophin trajectories, coping and depressive symptoms during primary treatment in women with ovarian or endometrial cancer. Methods: In this prospective study, 52 women (26 with ovarian and 26 with endometrial cancer) were assessed before surgery (T1) and before the first (T2), third (T3) and sixth (T4) cycles of carboplatin–paclitaxel chemotherapy. Serum β-NGF, BDNF, NT-3 and NT-4/5 were measured by ELISA; coping was assessed with the Mini-MAC scale and depressive symptoms with the BDI-II. Data were analysed using linear mixed-effect models and repeated-measures correlations. Results: Significant cohort × time interactions were observed for all four neurotrophins, most pronounced for β-NGF and NT-4/5, and several changes occurred during the perioperative period (T1–T2) rather than during chemotherapy. Within individuals, depressive symptoms correlated positively with destructive coping (r = 0.41–0.54) and negatively with fighting spirit (r ≈ −0.38), but not with any neurotrophin after correction for multiple testing. Conclusions: Neurotrophin trajectories differed between two clinically distinct treatment cohorts; because the cohorts also differed in age, surgical extent and adjuvant treatment, these differences cannot be attributed to tumour type alone. Depressive symptoms co-varied with coping style rather than with peripheral neurotrophin concentrations.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-18
DOI
https://doi.org/10.3390/jcm15229037
Primary Topic
Cancer survivorship and care
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Peripheral Neurotrophin Trajectories, Coping and Depressive Symptoms During Primary Treatment in Ovarian and Endometrial Cancer: A Prospective Longitudinal Study

Anna Jurczak, Anita Monika Chudecka-Glaz, Danuta Cembrowska-Lech, Sylwia Wieder-Huszla et al.
Journal of Clinical Medicine
Cancer survivorship and care
article

Peripheral Neurotrophin Trajectories, Coping and Depressive Symptoms During Primary Treatment in Ovarian and Endometrial Cancer: A Prospective Longitudinal Study

Anna Jurczak, Anita Monika Chudecka-Glaz, Danuta Cembrowska-Lech, Sylwia Wieder-Huszla, Aleksandra Kukla-Jakubowska
article en

Abstract

Background: Changes in peripheral neurotrophin concentrations during cancer treatment may reflect tumour biology, haematological alterations or systemic inflammation, and neurotrophins have been linked to depression. We examined neurotrophin trajectories, coping and depressive symptoms during primary treatment in women with ovarian or endometrial cancer. Methods: In this prospective study, 52 women (26 with ovarian and 26 with endometrial cancer) were assessed before surgery (T1) and before the first (T2), third (T3) and sixth (T4) cycles of carboplatin–paclitaxel chemotherapy. Serum β-NGF, BDNF, NT-3 and NT-4/5 were measured by ELISA; coping was assessed with the Mini-MAC scale and depressive symptoms with the BDI-II. Data were analysed using linear mixed-effect models and repeated-measures correlations. Results: Significant cohort × time interactions were observed for all four neurotrophins, most pronounced for β-NGF and NT-4/5, and several changes occurred during the perioperative period (T1–T2) rather than during chemotherapy. Within individuals, depressive symptoms correlated positively with destructive coping (r = 0.41–0.54) and negatively with fighting spirit (r ≈ −0.38), but not with any neurotrophin after correction for multiple testing. Conclusions: Neurotrophin trajectories differed between two clinically distinct treatment cohorts; because the cohorts also differed in age, surgical extent and adjuvant treatment, these differences cannot be attributed to tumour type alone. Depressive symptoms co-varied with coping style rather than with peripheral neurotrophin concentrations.

Journal of Clinical MedicineVol. 15(22)
Pomeranian Medical University (PL)
Good health and well-being
Cancer survivorship and care
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon